pre-ipo
Stage
2
Investors
About
Parabilis develops ultra-tunable peptide therapeutics based on their proprietary Helicon platform to target previously undruggable proteins, aiming to create novel medicines for diseases including cancer.
Explore Parabilis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.